KEEOGO™ NOW RECOGNIZED BY REVENU QUÉBEC FOR THE PURPOSES OF THE NON-REFUNDABLE TAX CREDIT FOR MEDICAL EXPENSES.
Québec City, QC | June 28 2017 – B-TEMIA Inc., a leader in the human augmentation market with its patented dermoskeleton technology, today announced that Revenu Québec has confirmed the eligibility of the Keeogo™ related expenses for the purposes of the non-refundable tax credit for medical expenses. While this decision only applies at the Quebec provincial level, it is an important step towards providing financial support for people who need and desire to acquire B-TEMIA’s Keeogo™ powered walking assistance device. According to current rules, the tax credit can amount to 20% of eligible medical expenses that exceed 3% of family net income. However, each situation being different, it is recommended to consult with an accountant to fully understand the impact of the tax credit on one’s income tax return. In parallel, B-TEMIA continues to work on obtaining the eligibility of Keeogo™ for the federal tax credit, and demonstrating the clinical and economic value of Keeogo™ in order to achieve coverage and reimbursement from private health insurers and other public programs.
About the Keeogo™ Dermoskeleton™
Keeogo™ is a powered walking assistance device developed by B-TEMIA. It has been used by individuals with degenerative and chronic medical conditions such as knee/hip osteoarthritis, multiple sclerosis, Parkinson’s disease, stroke, incomplete spinal cord injury (SCI) and other conditions that limit mobility. Used as rehabilitation equipment or as a daily commodity for walking, Keeogo™ is commercially available in Canada for purchase or rental. It is currently under investigation in a multicenter pivotal clinical trial aiming for Food and Drug Administration (FDA) clearance, a prerequisite to enter the US market.
Founded in 2010, B-TEMIA Inc. is a medical device manufacturer that develops and markets cutting-edge products for the growing market of human augmentation systems. B-TEMIA operates through two wholly-owned subsidiaries, B-TEMIA Inc. and B-TEMIA USA Inc., in the medical, industrial and military fields. B-TEMIA owns a patented technology called Dermoskeleton™ that restores, maintains or enhances the mobility of users.
Paule De Blois
Chef des opérations
Phone: (418) 653-1010, ext. 240